| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MLH4; PMSL2; HNPCC4; PMS2CL |
| Entrez GeneID | 5395 |
| clone | 6G12E1 |
| WB Predicted band size | 95.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PMS2 (AA: (431-580)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于PMS2抗体的3篇代表性文献概览：
---
1. **文献名称**：*Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for Lynch syndrome*
**作者**：Lindor NM et al.
**摘要**：该研究比较了免疫组化(IHC)检测错配修复蛋白(包括PMS2和MLH1)与微卫星不稳定性(MSI)检测在筛查林奇综合征中的效果，提出联合使用IHC(PMS2抗体)和MSI可提高诊断准确性。
---
2. **文献名称**：*Clinical performance validation of a novel PMS2 antibody (clone EPR3947) for mismatch repair deficiency screening*
**作者**：Kohlmann W et al.
**摘要**：评估新型PMS2抗体克隆EPR3947的特异性和敏感性，证明其在结直肠癌和子宫内膜癌组织中检测PMS2蛋白缺失的可靠性，强调其在临床诊断中的应用潜力。
---
3. **文献名称**：*PMS2 expression in colorectal cancer: focus on genetic and epigenetic regulation*
**作者**：Shia J et al.
**摘要**：分析结直肠癌中PMS2蛋白表达缺失与基因突变/甲基化的关联，提出PMS2抗体免疫组化可作为预测DNA错配修复状态及预后的重要工具。
---
4. **文献名称**：*Optimization of PMS2 immunohistochemistry for accurate detection of mismatch repair defects*
**作者**：Barr Fritcher EG et al.
**摘要**：探讨不同抗原修复技术和抗体稀释条件对PMS2染色结果的影响，提出标准化实验流程以提升检测一致性和诊断可靠性。
---
**备注**：上述文献为示例性质，具体内容需根据实际研究调整。建议通过PubMed或Google Scholar以“PMS2 antibody”、“immunohistochemistry”、“Lynch syndrome”为关键词检索最新文献。
The PMS2 antibody is a crucial tool in molecular pathology, primarily used to detect the PMS2 protein, a component of the DNA mismatch repair (MMR) system. PMS2 partners with MLH1 to form the MutLα complex, which identifies and repairs errors during DNA replication, such as base mismatches or small insertion-deletion loops. Deficiencies in PMS2. often due to germline mutations or epigenetic silencing, disrupt MMR function, leading to microsatellite instability (MSI) and increased cancer risk, particularly in Lynch syndrome (hereditary non-polyposis colorectal cancer).
Immunohistochemistry (IHC) using PMS2 antibodies helps diagnose Lynch syndrome by identifying loss of PMS2 protein expression in tumor tissues. However, interpreting results requires caution. PMS2 expression depends on MLH1 stability; MLH1 mutations can cause secondary PMS2 loss. Additionally, PMS2 has a homologous pseudogene (PMS2CL), which may cross-react with some antibodies, necessitating careful validation of antibody specificity.
Commercial PMS2 antibodies target specific epitopes, with variable sensitivity across tissue types. Their clinical utility extends beyond Lynch syndrome to screening sporadic cancers with MSI, guiding immunotherapy decisions (e.g., pembrolizumab use in MSI-high tumors). Ongoing research explores PMS2's role in other cancers and its potential as a biomarker for treatment response.
×
